Liquidia (LQDA) reported its second-quarter sales exceeded Wall Street expectations, with its lung disease treatment Yutrepia generating $170.4 million in sales, a 31% increase. The company continues its rivalry with United Therapeutics (UTHR), which produces a competing inhaled treatment for high blood pressure in the lungs.